Objective:To assess the results of laparoscopic sleeve gastrectomy (LSG) in morbidly obese patients in terms of surgical outcomes, weight loss, and improvement or remission from metabolic co-morbidities.

Materials and Methods: Data of 28 patients who underwent LSG during July 2012 to June 2017 were reviewed. Data collected were surgical outcomes (operative time, blood loss, hospital stay, complications and mortality rate).  Percentage of excess-weight loss (%EWL), and improvement or remission of metabolic co-morbidities were reported.

Results: No serious surgical adverse event or death was encountered. The mean %EWL was 54.4+16.8% at 2 years. The %EWL was significantly higher in the patients whose BMI ≤ 40 kg/m² than others at 1-year follow-up (64.7±18.1 vs 46.5±15.5; p-value 0.039). However, the     2-year %EWL difference was not significant (59.5±14.1 vs 50.3±18.2; p-value 0.232). At 2-year follow-up, the rate of improvement and remission of diabetes, dyslipidemia, and hypertension were 100%, 100%, and 46.2% respectively.

Conclusion: LSG is a safe surgical procedure and effective to correct obesity and its metabolic co-morbidities.